SEQUENCE LISTING

<110> FORTY SEVEN, INC.
      MCCAMISH, MARK
      V0LKMER, JENS-PETER
      
<120> MULTISPECIFIC AGENTS FOR TREATMENT OF CANCER

<130> 063673-544571

<150> US 62/824,213 
<151> 2019-03-26

<160> 12

<170> FastSEQ for Windows Version 4.0

        
<210> 1
<211> 5
<212> PRT
<213> Artificial Sequence

<220> 
<223> 5F9 heavy chain CDR1

<400> 1
Asn Tyr Asn Met His
 1               5  


<210> 2
<211> 17
<212> PRT
<213> Artificial Sequence

<220> 
<223> 5F9 heavy chain CDR2

<400> 2
Thr Ile Tyr Pro Gly Asn Asp Asp Thr Ser Tyr Asn Gln Lys Phe Lys
 1               5                  10                  15      
Asp
    


<210> 3
<211> 8
<212> PRT
<213> Artificial Sequence

<220> 
<223> 5F9 heavy chain CDR3

<400> 3
Gly Gly Tyr Arg Ala Met Asp Tyr
 1               5              


<210> 4
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> 5F9 light chain CDR1

<400> 4
Arg Ser Ser Gln Ser Ile Val Tyr Ser Asn Gly Asn Thr Tyr Leu Gly
 1               5                  10                  15      


<210> 5
<211> 7
<212> PRT
<213> Artificial Sequence

<220> 
<223> 5F9 light chain CDR2

<400> 5
Lys Val Ser Asn Arg Phe Ser
 1               5          


<210> 6
<211> 9
<212> PRT
<213> Artificial Sequence

<220> 
<223> 5F9 light chain CDR3

<400> 6
Phe Gln Gly Ser His Val Pro Tyr Thr
 1               5                  


     
<210> 7
<211> 117
<212> PRT
<213> Artificial Sequence

<220> 
<223> Humanized antibody hu5F9-vh1

<400> 7
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
            20                  25                  30          
Asn Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
        35                  40                  45              
Gly Thr Ile Tyr Pro Gly Asn Asp Asp Thr Ser Tyr Asn Gln Lys Phe
    50                  55                  60                  
Lys Asp Lys Ala Thr Leu Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65                  70                  75                  80  
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Gly Gly Tyr Arg Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu
            100                 105                 110         
Val Thr Val Ser Ser
        115         


<210> 8
<211> 117
<212> PRT
<213> Artificial Sequence

<220> 
<223> Humanized antibody hu5F9-vh2

<400> 8
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
            20                  25                  30          
Asn Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met
        35                  40                  45              
Gly Thr Ile Tyr Pro Gly Asn Asp Asp Thr Ser Tyr Asn Gln Lys Phe
    50                  55                  60                  
Lys Asp Arg Val Thr Ile Thr Ala Asp Thr Ser Ala Ser Thr Ala Tyr
65                  70                  75                  80  
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Gly Gly Tyr Arg Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu
            100                 105                 110         
Val Thr Val Ser Ser
        115         


<210> 9
<211> 117
<212> PRT
<213> Artificial Sequence

<220> 
<223> Humanized antibody hu5F9-vh3

<400> 9
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
            20                  25                  30          
Asn Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Ile
        35                  40                  45              
Gly Thr Ile Tyr Pro Gly Asn Asp Asp Thr Ser Tyr Asn Gln Lys Phe
    50                  55                  60                  
Lys Asp Arg Ala Thr Leu Thr Ala Asp Lys Ser Ala Ser Thr Ala Tyr
65                  70                  75                  80  
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Gly Gly Tyr Arg Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu
            100                 105                 110         
Val Thr Val Ser Ser
        115         



<210> 10
<211> 112
<212> PRT
<213> Artificial Sequence

<220> 
<223> Humanized antibody hu5F9-vl1

<400> 10
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
 1               5                  10                  15      
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val Tyr Ser
            20                  25                  30          
Asn Gly Asn Thr Tyr Leu Gly Trp Tyr Leu Gln Lys Pro Gly Gln Ser
        35                  40                  45              
Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
    50                  55                  60                  
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65                  70                  75                  80  
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr His Cys Phe Gln Gly
                85                  90                  95      
Ser His Val Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
            100                 105                 110         


<210> 11
<211> 112
<212> PRT
<213> Artificial Sequence

<220> 
<223> Humanized antibody hu5F9-vl2

<400> 11
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
 1               5                  10                  15      
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val Tyr Ser
            20                  25                  30          
Asn Gly Asn Thr Tyr Leu Gly Trp Tyr Leu Gln Lys Pro Gly Gln Ser
        35                  40                  45              
Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
    50                  55                  60                  
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65                  70                  75                  80  
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Phe Gln Gly
                85                  90                  95      
Ser His Val Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
            100                 105                 110         


<210> 12
<211> 112
<212> PRT
<213> Artificial Sequence

<220> 
<223> Humanized antibody hu5F9-vl3

<400> 12
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
 1               5                  10                  15      
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val Tyr Ser
            20                  25                  30          
Asn Gly Asn Thr Tyr Leu Gly Trp Tyr Leu Gln Lys Pro Gly Gln Ser
        35                  40                  45              
Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
    50                  55                  60                  
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65                  70                  75                  80  
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr His Cys Phe Gln Gly
                85                  90                  95      
Ser His Val Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
            100                 105                 110         




